Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation

European Journal of Pharmacology

Volumn 648, Issue 1-3, 2010, Pages 162-170

  Lee, In Ah ^a   Hyun, Yang Jin ^a   Kim, Dong Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

2,4,6 Trinitrobenzene sulfonic acid; Berberine; Lipid peroxidation; Lipopolysaccharide; NF B; TLR 4

Indexed keywords

BERBERINE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR 4; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BIFIDOBACTERIUM; CELL STIMULATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENTEROBACTERIACEAE; ENZYME ACTIVITY; GROWTH INHIBITION; INTESTINE EPITHELIUM CELL; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WEIGHT GAIN;

ANIMALS; BERBERINE; COLITIS; ENTEROBACTERIACEAE; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; INFLAMMATION; INTESTINES; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; TRINITROBENZENESULFONIC ACID;

EID: 77957726821     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.046     Document Type: Article

References (38)

1. Atreya R., Multer J., Fintoo S., Müllberg J., Jostock T., Wirtz S., Schütz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J.F., Lehr H.A., Autschbach F., Schürmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P.R., Rose-John S., Neurath M.F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 2000, 6:583-588.
2. Bae E.A., Han M.J., Kim N.J., Kim D.H. Anti-Helicobacter pylori activity of herbal medicines. Biol. Pharm. Bull. 1998, 21:990-992.
3. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract. Res. Clin. Gastroenterol. 2004, 18:463-479.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68:7010-7017.
6. Cernáková M., Kostálová D. Antimicrobial activity of berberine-a constituent of Mahonia aquifolium. Folia Microbiol. 2002, 47:375-378.
7. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 1999, 274:10689-10692.
8. Dabek M., McCrae S.I., Stevens V.J., Duncan S.H., Louis P. Distribution of β-glucosidase and β-glucuronidase activity and of β-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 2008, 66:487-495.
9. Domadia P.N., Bhunia A., Sivaraman J., Swarup S., Dasgupta D. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 2008, 47:3225-3234.
10. Fukata M., Chen A., Klepper A., Krishnareddy S., Vamadevan A.S., Thomas L.S., Xu R., Inoue H., Arditi M., Dannenberg A.J., Abreu M.T. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131:862-877.
11. Galle K., Muller-Jakic B., Proebstle A. Analytical and pharmacological studies on Mahonia aquifolium. Int. J. Phytomed. 1994, 1:59-62.
12. Han W., Mercenier A., Ait-Belgnaoui A., Pavan S., Lamine F., van Swam I.I., Kleerebezem M., Salvador-Cartier C., Hisbergues M., Bueno L., Theodorou V., Fioramonti J. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm. Bowel Dis. 2006, 12:1044-1052.
13. Hiraishi A. Direct automated sequencing of 16S rDNA amplified by polymerase chain reaction from bacterial cultures without DNA purification. Lett. Appl. Microbiol. 1992, 15:210-213.
14. Hollenbach E., Vieth M., Rosessner A., Neumann M., Malfertheiner P., Naumann M. Inhibition of RICK/nuclear factor-kB and p38 signalling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem. 2005, 280:14981-14988.
15. Ingalls R.R., Heine H., Lien E., Yoshimura A., Glenbock D. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect. Dis. Clin. N. Am. 1999, 13:341-353.
16. Jung H.C., Eckmann I., Yang S.K., Panja A., Fierer J., Morzycka-Wroblewska E., Kagnoff M.F. A distinct array of proinflammatory cytokine is expressed in human colon epithelia cells in response to bacterial invasion. J. Clin. Invest. 1995, 95:55-65.
17. Kawashima K., Nomura A., Makino T., Saito K., Kano Y. Pharmacological properties of traditional medicine (XXlX): effect of Hange-shashin-to and the combinations of its herbal constituents on rat experimental colitis. Biol. Pharm. Bull. 2004, 27:1599-1603.
18. Kim D.H., Jin Y.H., Jung E.A., Han M.J., Kobashi K. Purification and characterization of β-glucuronidase from Escherichia coli HGU-3, a human intestinal bacterium. Biol. Pharm. Bull. 1995, 18:1184-1188.
19. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
20. Kruidenier L., Kuiper I., Lamers C.B., Verspaget H.W. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 2003, 201:28-36.
21. Lee C.H., Chen J.C., Hsiang C.Y., Wu S.L., Wu H.C., Ho T.Y. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol. Res. 2007, 56:193-201.
22. Lee J.H., Lee B., Lee H.S., Bae E.A., Lee H., Ahn Y.T., Lim K.S., Huh C.S., Kim D.H. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int. J. Colorectal Dis. 2009, 24:231-237.
23. Mullane K.M., Kraemer R., Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 1985, 14:157-167.
24. Naito Y., Takagi T., Yoshikawa T. Molecular fingerprints of neutrophil-dependent-oxidative stress in inflammatory bowel disease. J. Gastroenterol. 2007, 42:787-998.
25. Ohkawa H., Ohishi N., Yoke K. Assay of lipid peroxidases in animal tissue by thiobarbituric acid reaction. Anal. Biol. Chem. 1978, 95:351-358.
26. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidases. J. Lab. Clin. Med. 1967, 701:158-169.
27. Pandey M.K., Sung B., Kunnumakkara A.B., Sethi G., Chaturvedi M.M., Aggarwal B.B. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68:5370-5379.
28. Park Y.J., Liu G., Lorne E.F., Zhao X., Wang J., Tsuruta Y., Zmijewski J., Abraham E. PAI-1 inhibits neutrophil efferocytosis. Proc. Natl Acad. Sci. U. S. A. 2008, 105:11784-11789.
29. Park Y.J., Liu G., Tsuruta Y., Lorne E., Abraham E. Participation of the urokinase receptor in neutrophil efferocytosis. Blood 2009, 114:860-870.
30. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
31. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 1189:615-625.
32. Radema S.A., van Deventer S.J., Cerami A. Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. Gastroenterology 1991, 100:1180-1186.
33. Rafii F., van Embdin R., van Lieshout L.M.C. Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments. Dig. Dis. Sci. 1999, 44:637-642.
34. Roessner A., Kuester D., Malfertheiner P., Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 2008, 204:511-524.
35. Shanahan F. Crohn's disease. Lancet 2002, 359:62-69.
36. Vollekova A., Kostalova D., Sochorova R. Isoquinoline alkaloids from Mahonia aquifolium stem bark are active against Malassezia spp. Folia Microbiol. 2001, 46:107-111.
37. Yu H.H., Kim K.J., Cha J.D., Kim H.K., Lee Y.E., Choi N.Y., You Y.O. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J. Med. Food 2005, 8:454-461.
38. Zhou H., Mineshita S. The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J. Pharmacol. Exp. Ther. 2000, 294:822-829.